Volume 2, Issue 7
Editorialp. 655-657
Small sample sizes in clinical trials, a statisticians perspective
Author(s): Lucinda Billingham, Kinga Malottki,Neil Steven
Editorialp. 663-665
Clinical innovation for neurodegenerative diseases
Author(s): Olivier Blin, Ceri H Davies, Bai Lu
News and Viewsp. 667–669
Drug to treat form of Gaucher disease gains FDA approval
Clinical Trail Perspectivep. 671-678
Psoriasis, a proof-of-principle condition for immune-mediated inflammatory disorders: perspectives toward optimal clinical trial design
Author(s): Kristen Corey, Peter Mattei, Neil Houston, Paul W Tebbey, Alan Menter, Peter CM van de Kerkhof, Alexa Boer Kimball
Clinical Trail Perspectivep. 679-687
Pharmacodynamic end points in early phase oncology trials
Author(s): Giovanna Speranza, James H Doroshow, Shivaani Kummar
Review: Clinical Trail Outcomesp. 689-705
Clinical trials and overactive bladder: lessons learned
Author(s): Ariana L Smith, Alan J Wein
Review: Clinical Trail Outcomesp. 707-713
Abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer: review of the clinical data
Author(s): D Schrijvers
Review: Clinical Trail Outcomesp. 715-731
Pharmacotherapy for adult acute lymphoblastic leukemia: an update from recent clinical trials and future directions
Author(s): Brian L Burnette, Mrinal S Patnaik, Mark R Litzow
Clinical Trail Methodologyp. 733-745
Considerations in the design of clinical trials for erectile dysfunction
Author(s): Naif Alhathal, Talal Al-Qaoud,Serge Carrier
Research Articlep. 747-752
Low-dose enteric-coated aspirin does not inhibit thromboxane B2 and prostaglandin E2: data-derived hypothesis formulation***Low-dose enteric-coated aspirin and platelets
Author(s): Charles H Hennekens, Scott Hetzel, Michael Pfeffer, Ricky Schneider, Steven Borzak, Wendy Schneider, Victor Serebruany,David DeMets
